Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs� fusion-protein science is fascinating—yet its SEC disclosures can be overwhelming. The company’s annual report details how the ARC® platform blocks immune checkpoints and activates costimulatory receptors, while pages of R&D spend obscure the real cash runway. If you have ever asked, “How do I read the Shattuck Labs annual report 10-K simplified?� or searched for “Shattuck Labs SEC filings explained simply,� this page was built for you.
Stock Titan’s AI-powered analysis converts technical language into plain English. Instantly surface the data that matters: Form 4 insider transactions real-time, quarterly burn rates from each Shattuck Labs quarterly earnings report 10-Q filing, and every Shattuck Labs 8-K material events explained alert the moment it hits EDGAR. Our models highlight when SL-172154 reaches a clinical milestone, flag collaboration revenue swings, and summarize risk-factor changes in seconds—so you spend time interpreting, not searching.
All filing types are here with live updates. Track Shattuck Labs insider trading Form 4 transactions to gauge management’s conviction, review the proxy statement executive compensation before voting, or dive into an earnings report filing analysis to compare trial costs quarter over quarter. Need context? Our concise AI summaries sit beside the full document, helping professionals understand complex disclosures quickly. Whether you’re monitoring Shattuck Labs executive stock transactions Form 4 or seeking a fresh lens on the annual report 10-K simplified, the intelligence you need is one click away.
Shattuck Labs (STTK) has entered into a private placement financing agreement dated 4 Aug 2025. The company will sell 15,225,158 common shares and issue pre-funded warrants for 37,410,188 shares plus common warrants for 52,635,346 shares. The securities are priced at $0.8677 per share/Common Warrant unit and $0.8676 per pre-funded warrant/Common Warrant unit, generating ~$46 million gross proceeds at closing before fees. Wedbush & Co. acts as placement agent.
Pre-funded warrants carry a $0.0001 exercise price and no expiry; common warrants have a $1.0846 exercise price and expire 30 days after Phase 1 SL-325 dose-escalation and Phase 2 trial-design data are publicly released. Warrant holders are subject to a 4.99% (optionally 9.99%) ownership cap, adjustable up to 19.99% with 61-day notice.
Closing is contingent upon FDA clearance of the SL-325 IND and other customary conditions. If all common warrants are exercised, Shattuck could raise an additional ~$57 million, pushing total potential gross proceeds above $100 million.
The Securities Purchase Agreement grants certain investors the right to designate directors upon closing. A separate Registration Rights Agreement obliges the company to file a resale registration statement within 30 days after closing and to keep it effective until all registrable securities are sold or freely tradable.
The issuance relies on the Section 4(a)(2)/Reg D exemption; all purchasers are accredited investors. No public offering is involved, and securities are subject to transfer restrictions until registered or exempt.
The Vanguard Group has filed a Schedule 13G reporting a 5.14 % passive stake in Sierra Bancorp (BSRR). As of 30 June 2025, Vanguard beneficially owns 710,636 common shares (CUSIP 82620P102). Voting authority is largely delegated: Vanguard reports 0 shares with sole voting power and 5,244 shares with shared voting power. Dispositive authority is higher, with 700,461 shares sole and 10,175 shares shared.
The filing classifies Vanguard as an investment adviser under Rule 13d-1(b)(1)(ii)(E). The shares are held in the ordinary course for advisory clients; no intent to influence control is stated. Ashley Grim, Head of Global Fund Administration, signed the filing on 29 July 2025.
Crossing the 5 % threshold elevates Vanguard to Sierra Bancorp’s largest known institutional holder, increasing free-float support and potentially enhancing trading liquidity. However, because the position is passive and there is no activism language, the disclosure is informational rather than strategic.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is the core focus of Shattuck Labs, Inc.?
How does the ARC® platform work?
Which therapeutic areas does Shattuck Labs target?
What distinguishes Shattuck Labs from other biotech companies?
Can you elaborate on the company’s product pipeline?
Does Shattuck Labs collaborate with other companies?
